Zhao Yishen, Wang Peiyao, Dionigi Gianlorenzo, Kou Jiedong, Li Changlin, Li Fang, Wang Tie, Tian Wen, Jiang Kewei, Wang Ping, Zhang Hao, Sun Hui
Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Translational Medicine in Surgery, Jilin Provincial Engineering,Laboratory of Thyroid Disease Prevention and Treatment, Changchun.
Division of Surgery, Istituto Auxologico Italiano IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico).
Int J Surg. 2025 Jan 1;111(1):439-449. doi: 10.1097/JS9.0000000000002084.
The survey aimed to elucidate the complete range of national practices, including all technical and non-technical aspects, as well as surgical stratification and maturation, of the use of intraoperative neuromonitoring (IONM) during thyroid surgery in China.
Six national questionnaires, developed by the Chinese Neural Monitoring Study Group (CNMSG) between 2015 and 2023, were used to collect and analyze data regarding the clinical application, education, and scientific research related to IONM in Chinese medical institutions.
Among the surveyed hospitals, 45% reported an average annual surgical volume exceeding 3000 cases, with 82.5% performing more than 80% of the surgeries for malignant thyroid tumors. Additionally, 97.5% of the hospitals reported a less than 3% incidence of postoperative hoarseness with IONM. Statistical analysis from 2011 to 2015 found that the incidence of postoperative hoarseness decreased by 30% in 2013 compared with 2011, when the technology was introduced. Preoperative and postoperative laryngoscopies were routinely performed by 82.5% and 15% of the hospitals, respectively. For 65% of the hospitals, the publication of the Chinese edition of neuromonitoring guidelines in 2013 prompted the utilization of IONM technology. An average annual number of IONM applications exceeding 500 cases (18.5% the average volume) was reported by 80% of the hospitals, while 62.5% reported a cumulative number of applications greater than 5000 cases (47.1% the average cumulative volume). Regarding technical parameters, 75% of the hospitals reported an intraoperative V1 amplitude of greater than 500 µV, and 70% reported an intraoperative loss of signal (LOS) rate of less than 3%. 92.5% of the surveyed hospitals believed that IONM could help identify dissociated nerves, and 95% of the surveyed hospitals believed that IONM could reduce nerve damage. However, 72.5% of the respondents thought that cost was the main limitation. Furthermore, 67.5% of the hospitals reported that half of their thyroid surgical team members were trained in IONM, with 17.5% reporting that all team members were trained. Areas for reinforced training included IONM research methods and directions (72.5%) and analysis and treatment of abnormal EMG signals (72.5%). Research projects related to IONM were conducted by 42.5% of the hospitals, while 52.5% had published papers on neuromonitoring.
IONM was independently and incrementally associated with the annual surgical volume. This survey emphasized the importance of national collaboration and/or a registry for the uptake, consolidation, and development of CNMSG consensus.
本调查旨在阐明中国甲状腺手术中使用术中神经监测(IONM)的全国性实践的全貌,包括所有技术和非技术方面,以及手术分层和成熟情况。
使用中国神经监测研究组(CNMSG)在2015年至2023年期间编制的六份全国性调查问卷,收集和分析中国医疗机构中与IONM相关的临床应用、教育和科研数据。
在接受调查的医院中,45%报告平均每年手术量超过3000例,82.5%的手术为甲状腺恶性肿瘤手术。此外,97.5%的医院报告IONM术后声音嘶哑发生率低于3%。2011年至2015年的统计分析发现,与2011年引入该技术时相比,2013年术后声音嘶哑发生率下降了30%。分别有82.5%和15%的医院常规进行术前和术后喉镜检查。65%的医院表示,2013年中文版神经监测指南的发布推动了IONM技术的应用。80%的医院报告IONM平均每年应用次数超过500例(占平均量的18.5%),而62.5%报告累计应用次数超过5000例(占平均累计量的47.1%)。关于技术参数,75%的医院报告术中V1波幅大于500μV,70%报告术中信号丢失(LOS)率低于3%。92.5%的受调查医院认为IONM有助于识别离断神经,95%的受调查医院认为IONM可减少神经损伤。然而,72.5%的受访者认为费用是主要限制因素。此外,67.5%的医院报告其甲状腺手术团队成员中有一半接受过IONM培训,17.5%报告所有团队成员均接受过培训。强化培训领域包括IONM研究方法和方向(72.5%)以及异常肌电图信号的分析和处理(72.5%)。42.5%的医院开展了与IONM相关的研究项目,52.5%发表了关于神经监测的论文。
IONM与年手术量独立且逐步相关。本次调查强调了全国合作和/或登记册对于CNMSG共识的采用、巩固和发展的重要性。